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Background. H. pylori causes gastritis and peptic ulcers and is a risk factor for the development of gastric carcinoma. Many of
the proteins such as urease, porins, flagellins and toxins such as lipo-polysaccharides have been identified as potential
virulence factors which induce proinflammatory reaction. We report immunogenic potentials of isocitrate dehydrogenase
(ICD), an important house keeping protein of H. pylori. Methodology/Principal Findings. Amino acid sequences of H. pylori
ICD were subjected to in silico analysis for regions with predictably high antigenic indexes. Also, computational modelling of
the H. pylori ICD as juxtaposed to the E. coli ICD was carried out to determine levels of structure similarity and the availability
of surface exposed motifs, if any. The icd gene was cloned, expressed and purified to a very high homogeneity. Humoral
response directed against H. pylori ICD was detected through an enzyme linked immunosorbent assay (ELISA) in 82 human
subjects comprising of 58 patients with H. pylori associated gastritis or ulcer disease and 24 asymptomatic healthy controls.
The H. pylori ICD elicited potentially high humoral immune response and revealed high antibody titers in sera corresponding
to endoscopically-confirmed gastritis and ulcer disease subjects. However, urea-breath-test negative healthy control samples
and asymptomatic control samples did not reveal any detectable immune responses. The ELISA for proinflammatory cytokine
IL-8 did not exhibit any significant proinflammatory activity of ICD. Conclusions/Significance. ICD of H. pylori is an
immunogen which interacts with the host immune system subsequent to a possible autolytic-release and thereby significantly
elicits humoral responses in individuals with invasive H. pylori infection. However, ICD could not significantly stimulate IL8
induction in a cultured macrophage cell line (THP1) and therefore, may not be a notable proinflammatory agent.
Citation: Hussain MA, Naveed SA, Sechi LA, Ranjan S, Alvi A, et al (2008) Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral
Immune Response in Subjects with Peptic Ulcer Disease and Gastritis. PLoS ONE 3(1): e1481. doi:10.1371/journal.pone.0001481
INTRODUCTION
Helicobacter pylori is a Gram negative, curved bacterium that
establishes chronic infections in human stomach. It is an important
pathogen that is thought to have co-evolved with humans [1,2]. It
inhabits about half of the world population and is considered as a
potential risk factor for the development of gastric adenocarcinoma
[3]. H. pylori is a recognized cause of chronic gastritis, peptic ulcer
disease, gastric carcinoma, and mucosa-associated lymphoid tissue
(MALT) lymphoma. Several mechanisms have been proposed to
explain its role in pathogenesis of the gut. Despite high colonization
rates only a small subset of infected people experience H. pylori-
associated diseases [2]. Associations of H. pylori with disease-specific
factors have remained more or less enigmatic even though the
genome sequences were deciphered almost a decade ago [2].
One of the most distinctive features of H. pylori is the genetic
diversity between clinical isolates obtained from different patient
populations [3]. Recasting of the genome is the norm with this
bacterium, creating thereby a lot of allelic and phase variation [3],
posing difficulties in the development of diagnostics and vaccines.
Once acquired, the infection persists for years and, elicits
detectable immune responses in infected persons [4,5] character-
ized by increased levels of specific IgG and IgA in serum and
augmentation of secretory IgA and IgM in stomach [6].
Therefore, noninvasive serological tests were recommended and
developed for the diagnosis of H. pylori infection. Among these, the
enzyme-linked immunosorbent assay (ELISA) is one of the most
extensively used method as it is relatively affordable, fast, simple to
perform, and could be easily adopted for screening large number
of samples [7]. Exploring for anti H. pylori antibodies is often
prescribed before endoscopy or before initiating treatment.
Although due to immunological memory, serodiagnosis may not
be preferred to check the success or outcome of eradication
treatment, it remains a choice as a sensitive method probably
because of its non-invasive nature [8].
Currently, there has not been any single ‘gold standard’ antigen,
which can unambiguously be used across all populations. One of
the important reasons for this could be the extraordinary diversity
present in H. pylori [9–13] and also its specific adaptation in
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different hosts [12,13]. Although proteins such as catalase, groEL,
and flagellin are strongly immunogenic, they give nonspecific
cross-reactions with other Gram-negative bacteria and, more
particularly, Campylobacter jejuni [14,15]. In contrast, virulence
linked antigens such as CagA or VacA, show quite a high degree of
sequence variability, as there exist H. pylori strains, which are
genetically diverse and phenotypically variable for one or both the
antigens [16–18]. Despite this, satisfactory associations between
serum antibodies and invasive disease have been described [19].
Housekeeping genes of H. pylori have been used recently to track
population migrations and were found to be stable in the genome
across centuries [20]. Housekeeping proteins however, have not
been tested by and large for their use in diagnostics or vaccines.
The metabolic enzymes seem to be a good candidate to be
included into an immuno-diagnostic test kit since they often do not
cross-react with sera from healthy controls [21]. Also, owing to
their housekeeping function, they are highly conserved among
different H. pylori strains irrespective of their genotypes and thus
can serve as ideal immuno-diagnostic candidates.
Proteins that are released from bacteria during late logarithmic
growth phase, such as superoxide dismutase and isocitrate
dehydrogenase (ICD), are described as autolysis markers [22–24]
and some of them have been proved to be excellent diagnostic
antigens. For example, ICD of M. tuberculosis has been described as
a potential antigen to discriminate pulmonary tuberculosis patients
from healthy controls [24]. However, previous comparisons of the
antigenic patterns of H. pylori proteins (including some of the
housekeeping proteins) recognized by patient sera revealed no
association of specific H. pylori antigens with cases of particular
gastroduodenal pathology [21].
This study demonstrates interaction of the host immune system
with H. pylori ICD in the form of significant humoral responses
seen in disease subjects. Further, we describe H. pylori ICD antigen
to distinguish ulcer disease and gastritis patients from uninfected
healthy individuals.
RESULTS
In silico modelling, expression and purification of H.
pylori ICD protein
Protein sequence of ICD of H. pylori was analyzed to predict its
immunogenicity based on antigenic index, hydrophilicity and
surface probability. Figure 1A shows in silico antigenic profiles of
ICD generated using Protean software (DNAStar Inc. USA).
Briefly, several traces corresponding to immunoreactive amino
acid motifs with predictably higher antigenic indices (,3.4) were
Figure 1. Computational analyses and homology modelling of the H. pylori and E. coli ICD protein sequences, structures and properties. A. The
two proteins were analyzed for different helices, coils and turns, hydrophilicity, antigenicity and surface probability etc. using Protean software in the
DNAstar package. Antigenicity index (Jameson-Wolf) of H. pylori ICD was found to be higher (3.4) than the E. coli ICD. B. We built a homology model
of the H. pylori ICD (Using Modeller 6) based on crystal structure of E. coli ICD (PDB code: 1AI2). Shown here is a comparison of backbone organization
of H. Pylori (26695) ICD with that of E. coli; E. coli (red), H. pylori (green), NADP (blue), ICA (yellow). Structures of the two ICDs were found to be
significantly different as regards to the surface exposed loops (RMS Deviation 0.45) corresponding to putative, immunogenic epitopes (arrows).
doi:10.1371/journal.pone.0001481.g001
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identified. The H. pylori ICD thus displayed major antigenic
stretches (Figure 1A) prompting us to look at it as a putatively
immunogenic protein. The antigenicity indices of ICD were
comparable to those previously reported for a PPE antigen
Rv2430c of mycobacterial origin, which was further proved to be
an immunodominant antigen [25]. The E. coli ICD was also
analyzed in a similar manner and appeared to be putatively
immunogenic; there was a clear difference found as compared to
H. pylori ICD, with respect to the abundance and position of
antigenic residues. Later, we constructed a homology model of the
H. pylori ICD based on the crystal structure of E. coli ICD (PDB
code 1AI2) and were able to portray backbone organization of H.
Pylori (26695) ICD along with that of E. coli. The two ICDs were
found to be significantly similar (RMS Deviation 0.45) yet differed
with respect to 3 important surface exposed loop regions which are
likely to constitute the areas of structural differences corresponding
to the putative antigenic epitopes, possibly imparting differential
antibody responses (Figure 1B).
The over-expressed N-terminal His-tagged ICD was purified to
.95% homogeneity on a nickel affinity column (Figure 2). The
molecular mass of the recombinant ICD was determined to be
47 kDa. Protein purification was carried out under native conditions
with a yield of 2.0 mg of protein per 500 ml of start culture.
Interaction of H. pylori ICD with the human immune
system
Humoral immune responses directed against the H. pylori ICD
were compared among patients with H. pylori infection (gastritis,
NUD, DU and GC) and healthy controls (Figure 3). The
immunoreactivity data were statistically analyzed and compared
with connection to both infected and healthy sera. These data
demonstrated that sera of all of the infected patients belonging to
gastritis and duodenal ulcer (DU) categories carried statistically
significant (P,0.0001) anti ICD antibody levels as compared to
those of the healthy controls. The ICD protein, which has an
apparently important metabolic role, was thus found to be able to
elicit a strong humoral response in subjects with gastritis and DU.
However, in cases of non-ulcer dyspepsia (NUD) and gastric
cancer (GC), reduced humoral response was seen. Given these
observations, it is likely that the release of ICD protein is
associated with active, H. pylori infection. In contrast to observed
humoral responses, the recombinant, H. pylori ICD did not induce
any significant cellular immune responses as evidenced from lack
Figure 2. Affinity purification of recombinant ICD of H. pylori. His-
tagged recombinant protein was purified under native conditions by
nickel column chromatography and stained with Coomassie blue after
10% SDS/PAGE. Lanes 1, 2 and 3: H. pylori ICD; lane 4: (M) protein
molecular mass marker with distribution 35, 45, 66.2 and 116 kDa
(beginning bottom).
doi:10.1371/journal.pone.0001481.g002
Figure 3. Specific antibody responses to ICD protein depicted as ELISA titers. Serum Antibodies were detected by the recombinant, H. pylori ICD in
sera samples of patients with gastroduodenal pathology such as gastritis and ulcer and were compared to clinically healthy individuals, 18 of those
were detected negative by UBA. Table in the inset reveals significance or otherwise of the student’s t test for the antibody titers obtained for various
disease conditions. Two tailed p values were obtained through student’s t test with a 95% power (level of significance) and a minimally significant p
value of 0.05.
doi:10.1371/journal.pone.0001481.g003
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of secretion of IL-8 from human macrophages induced with
recombinant, H. pylori ICD in vitro (Figure 4). We therefore, suggest
that ICD excites only the humoral compartment and may not
contribute to gastric pathology or cytokine induced changes in
gastric physiology.
DISCUSSION
Identification and characterization of highly immunogenic H.
pylori proteins is a compulsory requirement for the development of
serological tests based on recombinant purified antigens. Com-
bined with the urea breath test, serology is a noninvasive approach
to detect H. pylori infection, and several serological test kits based
on many different H. pylori antigens are commercially available.
Although the humoral immune response to H. pylori seems to be
quite variable, combinations of frequently recognized antigens
could prove useful for diagnostic purposes [21]. The metabolic
enzymes such as ICD seem to be good candidates to be harnessed
for serological test kit development mainly because they do not
cross-react with sera from non-infected or healthy individuals [24].
The significance of many immunogenic proteins of H. pylori
including some metabolic enzymes has not been appreciated much
in clinical samples in a previous proteomics based study [21]. Our
study was however directed to evaluate purified, recombinant, H.
pylori ICD for its immunological properties in different classes of H.
pylori infected acid peptic disease patients. We attempted to
systematically examine the presence and usefulness of immune
responses elicited by the ICD protein in H. pylori infected patients.
Our analysis using recombinant ICD of H. pylori revealed
significantly high antibody titers among peptic ulcer disease and
gastritis patients, as compared with NUD and cancer patients
(Figure 3). We speculate that the immune response seen in peptic
ulcer cases and gastritis could perhaps be due to high loads of
bacteria associated with invasive pathology and thereby a higher
number of autolysed pathogens or pathogens presenting ICD on
the surface. This may possibly explain the comparatively high-
antibody response in invasive category patients.
H. pylori antigens are described to be released into the
extracellular space via multiple mechanisms such as specific
secretion pathways, autolysis, and formation of membrane vesicles
[23] and the surface properties of H. pylori have been suggested to
be unique in allowing adsorption/surface localization of such
proteins [26]. ICDs are traditionally known as markers of autolysis
[22,24,27], released during the late logarithmic phase. The
extracellular release of proteins could potentially be occuring only
during in vitro growth of H. pylori. However, in vivo existence of such
mechanisms, if demonstrated, might be able to explain the role of
various secreted proteins in molecular pathology of ulcer disease.
The entry of H. pylori proteins into the gastric submucosal space
may have important functional consequences such as promotion of
proinflammatory and chemotactic responses through release of
cytokines from activated macrophages. Also, the extracellular
release and or adsorption or surface localization [26] of potentially
immunogenic proteins might support a bacterial strategy for
diverting an effective local immune response [23]. Keeping these
multiple mechanisms in mind, we checked proinflammatory
potentials of ICD with the help of an IL-8 ELISA assay. In our
observation, ICD did not significantly induce IL-8 secretion in
differentiated, cultured macrophages. However, since we did not
analyze role of ICD as regards to induction of other proinflamma-
tory cytokines such as TNF-a and IL1-b, it will be premature to justly
rule out its involvement in gastric inflammation.
Having shown that H. pylori ICD elicits a humoral response, we
investigated the basis of immune specificity of this protein as
reflected by structure based modelling. Our sequence analyses and
molecular modelling of H. pylori and E. coli ICDs did not reveal
complete structural overlaps between the two (Figure 1); several
regions of structural dissimilarities were discerned which possibly
correspond to the putative antigenic epitopes in H. pylori ICD.
Apart from the issues linked to structural conservation or diversity,
we hypothesize that higher reactivity of H. pylori ICD as compared
to ICD of (commensal) E. coli with the host immune system in vivo
could be associated with 1) different invasiveness of H. pylori and E.
coli 2) different magnitudes of bacterial load, turnover and autolysis
3) different repertoire of antigen presenting cells (macrophages
versus dendritic cells) involved and their relative abundance 4)
availability of surface exposed epitopes in H. pylori ICD (as those
highlighted in Figure 1B), and 5) presence of active lesions of
chronic inflammation, mucosal damage and chemotactic effects of
the other H. pylori proteins in the milieu.
While considering possible cross-reactivity from other invasive
bacteria such as C. jejuni, we tested H. pylori ICD against 8 samples
of C. jejuni enteritis patient sera and found that it did not cross-
react significantly (data not shown). The H. pylori free status of our
C. jejuni positive patients was determined based on the absence of
symptoms of indigestion, stomach pain and heartburn etc.
However, since we used only limited sera samples from C. jejuni
patients, we are not inclined to brand H. pylori ICD as a standalone
diagnostic antigen. Nonetheless, C. jejuni may not always comprise
a much competitive background unless C. jejuni patients themselves
are clinically colonized by H. pylori or vice-versa.
Finally, the promising results we obtained in terms of significant
humoral responses to H. pylori ICD may not be construed as
immediately applicable for field level diagnosis. Nonetheless, it is
possible that our findings provide a solid foundation for the
development of a sero-diagnostic test for H. pylori associated
gastroduodenal pathologies. We suggest the potential of this
antigen and its epitope specific peptides may further be analyzed
by using a large battery of sera samples representing different
disease subjects. Similarly, the status and significance of cross-
reacting antibodies in sera corresponding to illnesses caused by
Figure 4. Results of the IL-8 ELISA performed using cultured human
macrophages stimulated by the recombinant ICD of H. pylori. ELISA
titers from unstimulated (US) macrophages were used as negative
control and those from macrophages stimulated with a known
proinflammatory protein JHP940 [30] were used as a positive control.
ICD did not induce any significant IL-8 response as compared to control;
the JHP940 protein on the other hand revealed significantly high levels
of IL-8 as compared to ICD (p,0.0218).
doi:10.1371/journal.pone.0001481.g004
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bacteria such as Salmonella spp., Shigella spp. and other invasive
enteropathogens might also be determined. It will be worthwhile
to explore in-depth the involvement of ICD in signaling activities
in the submucosal space, specially its interaction with the activated
macrophages and lymphocytes. Also, given its important role in
the tricarboxylic acid cycle and the absence of glyoxylate shunt in
H. pylori [27], the evaluation of ICD as a possible interventional
target poses an exciting proposal.
MATERIALS AND METHODS
In silico antigenicity of predicted H. pylori ICD
(HP0023)
Nucleotide sequence of H. pylori icd (ORF HP0023) and the
corresponding amino acid sequence was obtained from Pylorigene
database (http://genolist.pasteur.fr) and was subjected to analysis
by DNAStar package (DNAStar Inc. Madison, USA). Amino acid
sequence of ICD was subjected to scrutiny for any antigenic
determinants using Protean program within the DNAStar
package. Parameters such as hydrophilicity, surface probability
and antigenic index were calculated for the entire protein using
this software. Antigenic indices showing more than 2 peaks at
.3.0 scales were considered as significantly more antigenic.
Computational modelling of ICD structure
Using Modeller-6, a molecular modelling program that imple-
ments an automated approach to comparative protein structure
modelling by satisfaction of spatial restraints [28] was used for
determining the three dimensional model of H. pylori ICD. The
ICD model of H. pylori was generated based on the E. coli ICD
template 1A12 which shares overall 68% sequence identity with
the H. pylori ICD.
Production of recombinant H. pylori ICD
The ORF corresponding to H. pylori icd (HP0023, 1.275 kb) was
amplified by PCR from the genomic DNA of a H. pylori patient isolate
MS8. The recombinant ICD protein was over expressed in E. coli and
purified to homogeneity (Figure 2) according to the methods
previously described by Banerjee et al [24]. The harvest of purified
protein was standardized up to 2.0 mg of purified protein per 500 ml
of starting culture of recombinant E. coli. The purified recombinant
protein was dialyzed against 20 mM Tris HCl, pH 7.5, with
100 mM NaCl and 3% glycerol. Further, the purified protein was
treated with polymixin B to rule out effects of any LPS
contamination. The purified recombinant ICD was lyophilized and
immediately stored frozen for downstream use in clinical diagnosis.
Patients and human serum samples
The study population (n= 82) comprised 58 H. pylori infected
patient samples (for details of number of cases analyzed in each
category, please see Figure 3) obtained from cases reporting
mainly to the Deccan College of Medical Sciences and Allied
Hospitals, (DCMS), Hyderabad, and 24 clinically healthy donors.
The healthy control group was comprised of 18 proven H. pylori
negative cases tested with Urea Breath Assay (UBA) and 6
asymptomatic individuals who were confirmed H. pylori negative as
tested by commercially available ELISA kit (Pyloriset EIA-GIII,
Orion, Espoo, Finland). In all the patient groups, diagnosis of ulcer
or gastritis was confirmed or ruled out by endoscopy by the
attending gastroenterologist. The presence of H. pylori in diseased
subjects included in this study was previously confirmed by Gram’s
staining, a rapid urease test (RUT), 16S rRNA and cagA gene
based PCRs and culture [29]. The study population had no sex or
age bias. Written informed consents were obtained from all the
patients and healthy controls at the respective centres.
ELISA for humoral responses
ELISA assay was performed to check the humoral immune
response in humans against recombinant ICD. Briefly, the 96-well
microtiter plates were coated with ,500 ng of recombinant ICD
protein. The coated plates were incubated overnight at 4uC,
washed three times with PBS-T (0.05% Tween 20 in 16PBS) and
twice with PBS. Plates were then blocked with 100 ml of blocking
buffer (2% BSA in 16 PBS) at 37uC for 2 hrs. The plates were
washed three times with wash buffer PBS-T and twice with PBS.
The H. pylori-infected human sera belonging to different clinical
groups were serially diluted (1:50, 1:100, 1:200 and 1:400) in
blocking buffer (1% BSA in PBS), to obtain optimum titers.
Diluted sera [50 ml of 1:200 diluted sera] were added to antigen-
coated wells and incubated for 1 hr at 37uC. The plates were
rinsed thrice with PBS-T and twice with PBS and further
incubated with anti-human IgG-horseradish peroxidase (Sigma)
at 37uC for 1 hr. Horseradish peroxidase activity was detected
using a chromogenic substance, o-phenylenediamine tetrahy-
drochloride (Sigma) in citrate-phosphate buffer (pH 5.4) and
H2O2 as 1 ml/ml. The reactions were stopped by using 0.5 M
H2SO4, and the absorbance values were measured at 492 nm in
an ELISA reader (Bio-Rad). Each ELISA was repeated at least
twice with all clinical sera isolates. Student’s t test was performed
to calculate p values based on the means of the serum antibody
titers corresponding to healthy and infected classes by using the
online scientific calculator of GraphPad (www.graphpad.com_-
quickcalcs_ttest1.cfm). P values less than 0.05 were considered
statistically significant.
ELISA for proinflammatory cytokine IL-8
THP-1 cells (human Monocyte, ATCC TIB 202) were grown and
maintained in RPMI 1640 (Invitrogen) supplemented with 10%
fetal bovine serum, 2 mM Glutamine and 1% anti-bacterial and
anti-mycotic solution (Gibco). For macrophage like stage,
approximately 161026 cells/well were differentiated using 5 ng/
ml Phorbol-12 myristate 13c acetate (PMA, Sigma). After
24 hours, cells were washed once with RPMI 1640 media and
stimulated using 10 mg/ml of recombinant ICD. A proinflamma-
tory protein, HP940, of H. pylori [30], purified under similar
conditions was used as a positive control (1 ug/ml). Cells were
incubated for 24 hours in a humidified atmosphere at 37uC. Cells
without protein treatment (unstimulated cells) served as negative
control. Culture supernatant collected after 24 hours was used for
the estimation of IL-8 using commercially available optEIA ELISA
Kit (BD Biosciences). Assay was performed according to the
instruction of manufacturer and the cytokine levels were calculated
using the recombinant standard provided in the kit. Sensitivity of
IL-8 was 3.1 pg/ml. Values were expressed as mean6 SD.
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